Neurocrine Biosciences
San Diego, California, U.S. | |
Key people | William Rastetter, Chairman Kevin C. Gorman, CEO |
---|---|
Revenue | US$788 million (2019) |
Number of employees | 1,350 (June 30, 2023) |
Website | neurocrine |
Footnotes / references [1][2] |
Neurocrine Biosciences, Inc. is an American
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia[5] and with a partner for endometriosis and uterine fibroids.[6]
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies,[7] and Lawrence Steinman of Stanford University.[8][9] The company was backed by Avalon Ventures among others.[8]
In 1995, the company collaborated with Belgium-based
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.[12]
In July 2001, Neurocrine and
In December 2002, Neurocrine reached an agreement with
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.[20]
On June 16, 2010, Neurocrine agreed to a deal with
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD.[24] Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.[25]
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.[5][26]
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women.[27][28] In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018.[29] The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.[6]
Product pipeline
- Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids[6]
- catechol-O-methyl transferase inhibitor in trials for Parkinson's disease[5]
- NBI-74788 – Corticotropin-releasing factor (CRF) receptor agonist[30]
References
- ^ a b "Company Overview of Neurocrine Biosciences, Inc". Bloomberg Business. Retrieved May 13, 2018.
- ^ "Neurocrine Biosciences Revenue 2006-2021 | NBIX".
- ^ Adams, Ben (August 30, 2016). "Neurocrine Submits Valbenazine NDA Early, Set For 2017 Approval". FierceBiotech. Retrieved May 13, 2017.
- ^ "FDA Approves New Strength for Tardive Dyskinesia Drug". Pharmacy Times. October 6, 2017. Retrieved May 13, 2018.
- ^ a b c "Neurocrine Nabs BIAL's PD Therapy Opicapone for North America". Genetic Engineering & Biotechnology News. February 10, 2017. Retrieved May 13, 2018.
- ^ a b c Inacio, Patricia (November 13, 2017). "Elagolix Improves Uterine Fibroid Symptoms With and Without Add-Back Therapy, Trials Show". Endometriosis News. Retrieved May 13, 2018.
- ^ "Wylie Vale". SALK. January 6, 2012.
- ^ a b Veggeberg, Scott (April 5, 1993). "Betting on Biotech". The Scientist.
- ^ "Executive Profile Lawrence Steinman". Bloomberg. Retrieved June 5, 2018.
- ^ "Company Briefs". The New York Times. February 17, 1995.
- ^ "Neorocrine Biosciences Raises $34.2 mm in IPO of 3.5mm Shares". Scrip Pharma Intelligence. May 1996.
- ^ "Lilly Paying for Obesity and Alzheimer Study". The New York Times. October 22, 1996.
- ^ "Neurocrine Biosciences and GlaxoSmithKline Announce Worldwide Collaboration For CRF Receptor Antagonists INcluding the Phase I Compound NBI-34041". Evaluate Group. July 24, 2001.
- ^ Chartrand, Sabra (June 17, 2002). "Patents; An Insomnia Drug, Based on a Patented Chemical Compound, Also Receives Protection". The New York Times.
- ^ Crabtree, Penni (March 23, 2004). "Helping People to Sleep Could Earn Neurocrine Big Bucks". San Diego Union Tribune.
- ^ "Company News; Pfizer is Buying Rights to Experimental Insomnia Drug". The New York Times. December 20, 2002.
- ^ "Pfizer Dumps Neurocrine, Shares Plunge". Forbes. June 22, 2006.
- ^ "Neurocrine Receives Approvable Letter for Indiplon Capsules With Additional Safety and Efficacy Data Required by FDA". Drugs.com. December 13, 2007.
- ^ "Neurocrine Biosciences and Dainippon Sumitomo Pharma Announce Agreement to Develop and Commercialize Indiplon in Japan". Reuters. November 1, 2007.
- ^ "Neurocrine Biosciences, Inc. Says CEO to Step Down". BioSpace. January 15, 2008.
- ^ Carroll, John (January 7, 2014). "Neurocrine Shares Soar with a Promising Second Take on a PhIIb Drug". FierceBiotech.
- ^ Gellene, Denise (June 16, 2010). "Neurocrine Inks Deal with Abbot". Xconomy.
- ^ "Abbot and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolic for the Treatment of Endometriosis". FierceBiotech. June 16, 2010.
- ^ Al Idrus, Amirah (January 2, 2018). "After Disappointing 2016, New Drug Approvals Roared Back to Life in 2017". FierceBiotech.
- ^ "Brief-Neurocrine Granted FDA Orphan Drug Designation for Valbenazine". Reuters. October 23, 2017.
- ^ "Brief-Neurocrine and Bial Reports Exclusive North American Licensing Agreement for Opicapone". Reuters. February 9, 2017.
- ^ Melao, Alice (September 7, 2017). "AbbVie Files for FDA Approval of Elagolix to Treat Endometriosis-associated Pain". Endometriosis News.
- ^ Moore, Charles (August 25, 2016). "Endometriosis Therapy Candidate Elagolix Meeting Phase 3 Clinical Trial Primary Targets". Endometriosis News. Retrieved 14 October 2016.
- ^ "AbbVie : FDA moves the goal line on AbbVie's endometriosis drug elagolix". 4-traders. April 11, 2018.
- ^ "NBI-74788". Biocentury. Retrieved May 13, 2018.
External links
- Official website
- Business data for Neurocrine Biosciences, Inc.: